TABLE 3.

Comparison of dose reductions, discontinuations and hepatitis C virus treatment outcomes between controls and oral cannabinoid-containing medication (OC) recipients

	No OC prescribed, % (n/total)	OC recipients, % (n/total)	P
Patients requiring interferon dose reductions	5 (8/166)	8 (2/25)	NS
Patients requiring ribavirin dose reductions	10 (17/166)	8 (2/25)	NS
At least 12 weeks of therapy completed*	89 (118/132)	94 (17/18)	NS
Full duration of therapy completed*†	49 (65/132)	78 (14/18)	P=0.02
Sustained virological response achieved†‡	52 (53/101)	79 (11/14)	P=0.07

Significance was defined as P<0.05.

^*Patients still on therapy at the time of data censorship were not included in this analysis (n=34 in the non-OC group and n=7 in OC recipients);

^†The full duration of therapy was 48 weeks for genotypes 1 and 4, and 24 weeks for genotypes 2 and 3;

^‡Patients who did not yet reach the six months after completion of therapy point at the time of analysis have been excluded. NS Not significant